• Most Popular
  • Most Shared

India Ranbaxy settles with GlaxoSmithKline on Imitrex

Mon Jan 21, 2008 12:11am EST

Stocks

   

MUMBAI, Jan 21 (Reuters) - Indian drugmaker Ranbaxy Laboratories Ltd (RANB.BO) said on Monday it had settled with GlaxoSmithKline (GSK.L) on a possible patent litigation for a generic version of the firm's Imitrex tablets, propping its share up in a falling market.

Stocks

Under the terms of the settlement, Ranbaxy may sell a generic version, sumatriptan succinate tablets, in multiple strengths in the United States from December 2008, it said in a statement.

Other terms of the settlement agreement were not disclosed.

Annual sales of Imitrex were $985 million, Ranbaxy estimates.

At 0510 GMT, Ranbaxy's shares were up 0.9 percent at 390 rupees, while the benchmark index .BSESN was down 2.8 percent. (Reporting by Rina Chandran; Editing by Charlotte Cooper)

Stocks


More from Reuters

Photo

Rajaratnam pleads innocent in Galleon case

NEW YORK (Reuters) - Galleon hedge fund founder Raj Rajaratnam and co-defendant Danielle Chiesi pleaded innocent on Monday to charges of securities fraud in what U.S. prosecutors describe as the biggest hedge fund insider trading case ever.

» More Top News
Demonstrators protest against the healthcare bill outside the Capitol in Washington December 15, 2009. REUTERS/Kevin Lamarque

Health bill passes crucial test

A sweeping U.S. healthcare reform bill appears headed for passage in the Senate after surviving a middle-of-the-night test vote.  Full Article | Video 

Healthcare Reform
Two men shake hands in a file photo. REUTERS/File

Let's make a deal

The battered M&A sector will make a tepid recovery in the coming year and three hot sectors will lead the way, according to a Thomson Reuters analysis.  Full Article 

Global Deals Review